A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis

Peter RouseReal World Solutions, IQVIA, London, UK

Peita Louise Graham-ClarkeGlobal Patient Reported Outcomes and Real World Evidence (GPORWE) International, Eli Lilly, West Ryde, AustraliaView further author information

Claudia NicolayInternational Statistics, Lilly Deutschland GmbH, Bad Homburg, GermanyView further author information

Walid FakhouriGlobal Patient Reported Outcomes and Real World Evidence (GPORWE) International, Eli Lilly, Windlesham, UKView further author information

Citations (1)

Keep up to date with the latest research on this topic with citation updates for this article.